Use of synthetic vectors to deliver genomes of conditionally replicating lytic viruses combines the strengths of viral and non-viral approaches by enabling neutralising antibody resistant deployment of cancer virotherapy. Adenovirus is particularly suitable for this application since all proteins essential for replication can be expressed from the input DNA, although the presence of terminal protein (TP) covalently linked to the 5 0 termini of the input virus genomes both improves expression of transgenes encoded in the input DNA and also enhances replication. These roles of TP were distinguished in experiments where E1-deleted Ad GFP DNA bearing TP (Ad GFP DNA-TP), delivered with DOTAP, gave a two-fold greater frequency of transduction than Ad GFP DNA(without TP) in non-complementing A549 cells, while in 293 cells (which support replication of E1-deleted viruses) the presence of TP mediated a much greater differential transgene expression, commensurate with its ability to promote replication. Subsequent studies using AdDNA for virotherapy, therefore, included covalently linked TP. AdDNA-TP delivered to A549 cells using a synthetic polyplex vector was shown to be resistant to levels of neutralising antisera that completely ablated infection by wild-type adenovirus, enabling polyplex/ Ad wild type DNA-TP to mediate a powerful cytopathic effect. Similarly in vivo, direct injection of a polyplex/Ad wild type DNA-TP into A549 tumours was neutralising antibodyresistant and enabled virus replication, whereas intact virus was neutralised by the antibody and failed to infect. The delivery of adenovirus genomes-TP using synthetic vectors should provide a strategy to bypass neutralising antibodies and facilitate clinical application of replicating adenovirus for cancer virotherapy. Gene Therapy (2006) 13, 1579-1586.
Introduction
Adenovirus promises to be an efficient and versatile vector for cancer gene therapy. It is suitable for a range of treatment modalities including delivery of wild-type copies of tumour suppressor genes or transgenes encoding proteins designed to kill the transduced cell, through either immunological or pharmacological means. 1 In addition adenovirus capable of cancer-specific replication can mediate a cytolytic anti-tumour activity, so called 'virotherapy'. [2] [3] [4] Each of these approaches can combine selectivity, through transductional and transcriptional targeting, with potency gained through enzymatic or replicative activity of the therapeutic agent at the target site. However, despite their great promise these approaches have shown only limited signs of therapeutic value in early clinical trials. [5] [6] [7] One of the major factors restricting the success of adenovirus gene therapy of cancer, particularly for intravascular delivery protocols, is the presence of neutralising anti-adenovirus antibodies. Most adults have significant levels of adenovirus-neutralising antibodies, the result of exposure to environmental adenovirus early in life, which can exert a profound inhibition of infection levels and contributes to rapid and effective neutralisation of the vector. [8] [9] [10] Several approaches are being studied to overcome this problem, including the use of non-human adenovirus or rare serotypes to avoid neutralisation by pre-existing antibodies. Other groups, including ourselves, are exploring physical coating of adenovirus with polymers to protect them from antibody recognition and enable systemic delivery. [11] [12] [13] [14] In contrast, fully synthetic vectors have already been shown to be capable of intravenous delivery of plasmid DNA 15 and have the advantage that cellular tropism can be tailored for specific applications. 16 Recently, we have developed synthetic polymer-based delivery vectors designed to combine robust stability during the delivery phase with activation by reduction following entry into cells, enabling triggered disassembly and cell-specific expression of transgenes. 17 However, despite attractive pharmaceutical properties, the usefulness of synthetic vectors is usually limited by the low levels of transgene expression they achieve.
It is conceivable to combine the useful attributes of viral and synthetic gene delivery strategies by employing a synthetic vector to deliver viral genomes. Although delivery of non-replicating virus genomes in this way would have no obvious advantage over delivery of the corresponding plasmids, the approach could be particularly useful for the delivery of replicating genomes. Subsequent replication of the virus in situ should amplify the therapeutic potency and enable a site-specific cytolytic virotherapy. Combining the superior pharmacokinetics of synthetic vectors with the tumouricidal activity of conditionally replicating adenovirus could produce a useful and effective strategy for treatment of metastatic cancer.
The adenovirus virion is comprised of many proteins, a subset of which enters the nucleus with the infecting genome and is involved in enabling its transcription and replication. One such component is terminal protein (TP), a 55 kDa protein linked covalently to each 5 0 terminus of the linear adenovirus genome, 18 known to be essential for virus replication and thought also to play a role in transcription. [19] [20] [21] [22] [23] [24] Sharp et al. 25 showed that removal of TP from the ends of the adenovirus genome reduced the frequency of plaque formation following calcium phosphate-mediated transfection of cells using adenovirus DNA. Accordingly it seems likely that in order to optimise virotherapy using adenovirus DNA within a synthetic vector, TP should be present at the DNA termini. In the present study, we show that the presence of TP mediates a significant enhancement in adenovirus gene expression, most notably in cells permissive for replication. We also demonstrate that delivery of adenovirus DNA with TP (AdDNA-TP) using synthetic delivery vectors is resistant to neutralising antibodies and can enable production of replicating adenovirus in situ that leads to a powerful cytopathic activity.
Results
Influence of TP on transgene expression from adenovirus DNA in non-complementing cells It has been reported that TP plays a role in localising adenovirus DNA within the nuclear matrix, potentially enhancing both transcription and virus replication. 19, 22, 26, 27 To characterise the effect of TP on expression of transgenes encoded within the input virus DNA, we used DNA from an E1-deleted reporter virus expressing Green Fluorescence Protein (Ad GFP DNA) and compared GFP expression following transfection of cells using DOTAP/DNA with and without covalently linked TP. The experiment was performed in non-complementing A549 cells to prevent effects due to virus replication. The presence of covalently linked TP resulted in a two-to threefold increase in the frequency of cells expressing GFP (up to 1.5% of cells; Figure 1a ), although it did not affect the mean fluorescence intensity per positive cell ( Figure  1b ). This suggests that TP has a small but measurable effect on enhancing transfection, possibly by increasing nuclear import of adenovirus DNA or by enhancing localisation to sites of transcription within the nucleus.
Application of pTP to gene transfer using plasmid DNA To assess whether the ability of TP to potentiate transgene expression from viral DNA could be transferred to plasmid systems, adenovirus preterminal protein (pTP) was linked covalently to the ends of linearised plasmids following incorporation of aminoallyl-modified dUTP (see Materials and methods). pTP was used instead of TP because the mature protein is poorly water soluble and not readily amenable to manipulation, while pTP has been shown to have a high affinity for the nuclear matrix. 27 Covalent attachment of pTP to linearised plasmid expressing GFP gave a fivefold increase in the frequency of transduced A549 cells (Figure 2) , reminiscent of the ability of TP to improve the transfection activity of input DNA (Figure 1a) . The same effect was not observed by simply mixing the pTP with the linearised plasmid, indicating that the pTP acts in conjunction with the DNA, and not via a more general cellular effect. However a similar increase in transfection frequency was achieved following covalent attachment of albumin to the DNA (Figure 2 ), suggesting that proteins can mediate a non-specific augmentation, possibly due to the protein protecting the ends of the plasmid from DNAse degradation. 25 demonstrated that plaque formation by AdDNA is far more efficient when TP is linked to the input DNA. However, plaque formation is dependent on the efficiency of the initial gene delivery event, as well as early gene transcription and genome replication. Hence, it is not possible to deduce the relative importance of TP to each of these processes directly from these data. The influence of TP on replication of adenovirus DNA was therefore assessed directly by comparing GFP expression in 293 cells, which support replication of this E1-deleted adenovirus ( Figure  3) , with that in A549 cells, which do not (Figure 1 ). In 293 cells the presence of TP produced a threefold increase in the frequency of positive cells after 24 h, (Figure 3a ) similar to that observed in non-complementing A549 cells (Figure 1a ). This suggests that TP was mediating similar effects on cellular distribution of the input DNA in both cell types, although 293 cells were generally easier to transduce. However, the presence of TP led to a time-dependent increase in the frequency of transgene expression in 293 cells, reaching over a sixfold enhancement by 110 h (Figure 3a ). This effect was not seen in A549 cells, and is compatible with a requirement for TP linked to the input adenovirus DNA to enable replication, thereby increasing the infective spreading of virus from cell to cell. Increased intercellular spread was clearly visible on scanning cell populations for GFP expression ( Figure 3c ) leading eventually to plaque formation. The amount of transgene expression per positive cell also increased markedly between 24 and 120 h in 293 cells, commensurate with increasing viral copy numbers in infected cells with newly replicated DNA acting as a template for transcription ( Figure 3b ).
Antibody-resistant cell transduction using adenovirus DNA delivered with DOTAP
The effects of anti-adenovirus neutralising antibodies on transgene expression by intact virus and Ad GFP DNA-TP delivered using DOTAP were compared ( Figure 4 ). 293 cells were incubated with intact virus (3000 genome copies/cell) or DOTAP/Ad GFP DNA-TP (10 000 and 100 000 genome copies per cell) both in the presence and absence of neutralising antibody. The frequency of transduction was assessed after 24 h by flow cytometry. Intact adenovirus achieved high levels of transduction in the absence of antibody, showing transgene expression in over 65% of cells, with a mean fluorescence intensity (MFI) above 400 mV. However, the presence of neutralising antibody ablated this infection, decreasing the frequency of GFP transduction to background. In contrast the use of DOTAP/Ad GFP DNA-TP achieved a lower transduction frequency in the absence of antibody (the maximum achieved was 55%, MFI 70 mV), but was far more resistant to neutralising antibody. In the presence of neutralising antibody DOTAP/Ad GFP DNA- Synthetic vectors for neutralising antibody resistant RC Carlisle et al TP achieved up to 20% frequency of cells transduced, with an MFI of 60 mV. Quantifying these effects showed that transgene expression by intact virus was inhibited over ten thousand fold by the antiserum, whereas DOTAP-based delivery was inhibited only approximately two fold. Even this two-fold inhibition of DOTAP delivery was unexpected, and may reflect the presence of anti-TP antibodies in the antiserum and imply the TP within the DOTAP/DNA complex is at least partially accessible for antibody-binding.
Antibody-resistant delivery of adenovirus virotherapy
The data shown in Figure 4 demonstrates that use of simple synthetic vectors such as DOTAP to deliver AdDNA-TP can provide a dramatic improvement in resistance to neutralising antibodies. While DOTAP is a non-specifically active agent, this observation opens the possibility of using ligand-targeted polyelectrolyte ('polyplex') systems for antibody-resistant receptor-specific delivery of adenovirus genomes both in vitro and in vivo. We therefore, assessed whether a basic fibroblast growth factor-retargeted (FGF) polymer-coated polyethylenimine/DNA polyplex could be used to deliver wild-type adenovirus genomes (AdwtDNA-TP), in the presence of neutralising antibodies, to achieve a cytopathic effect ( Figure 5 ). This polyplex is stabilised using disulphide bonds, enabling triggered disassembly and unpackaging within the reducing intracellular environment. 17, 28 Intact wild-type adenovirus or FGF retargeted polyplex/AdwtDNA-TP was delivered to A549 cells (0.1-10 000 genome copies per cell) in the presence of neutralising antisera. The infection media/antisera were then removed and cells were incubated in fresh medium. After 11 days the intact adenovirus had caused an extensive cytopathic effect when it was applied in the absence of antibody, even when low genome to cell infection ratios were used ( Figure 5 ; filled triangles). However, it achieved no significant cell killing when applied in the presence of antiserum (empty triangles), even at a genome to cell ratio of 10 000 to 1. When FGF retargeted polyplex/AdDNA-TP was used, higher genome to cell ratios were required to achieve complete monolayer destruction, but the destruction was independent of whether the vector was applied in the presence or absence of neutralising antisera.
To evaluate whether this polyplex system can achieve the same resistance to antibody-mediated neutralisation in vivo, samples of E1-deleted intact Ad luc or FGFpolyplex/Ad luc DNA-TP were pre-mixed with neutralising antibody and directly injected into A549 tumours ( Figure 6 ). Levels of infection were assessed by measuring luciferase activity after 48 h. In the absence of antibody (black bars) the levels of transgene expression achieved by intact Ad luc were much higher than those achieved using the equivalent genome number of FGF retargeted polyplex/Ad luc DNA-TP (3 Â 10 5 compared with 2 Â 10 2 pg luc/mg tumour). However, in the presence of antibody (empty bars) Ad luc infection was inhibited about 10 000-fold, whereas transgene expres- adenovirus genomes were detected, although no virus genomes were detected following injection of the same number of particles of replication-incompetent intact Ad luc . This suggests that non-replicating virus is lost quickly from the tumours, either by drainage or by degradation, but that the FGFpolyplex/AdDNA-TP vector is capable either of selective retention or replication enabling amplification of the input virus genomes. In addition tumours injected with the FGF-polyplex/AdDNA-TP showed intriguing signs of central necrosis, not observed when whole intact replication defective Ad luc was injected (data not shown).
Discussion
This study shows that synthetic vectors can be used to deliver replication competent adenovirus genomes, providing the opportunity to combine the superior pharmaceutical properties of non-viral vectors with the therapeutic power of oncolytic viruses.
Terminal protein, covalently linked to the ends of the adenovirus genome, was confirmed as a key component enabling the delivered DNA to efficiently enter the replicative cycle. The presence of TP covalently linked to Ad GFP DNA mediated an increased frequency of transduction of non-complementing A549 cells, but did not increase the average level of fluorescence per positive cell (Figure 1 ). This extends the findings of Schaack et al. 22 who found that the presence of TP enhanced the production of early gene mRNA from wild-type AdDNA but could not conclude whether this was the result of an increase in the number of transduced cells or an increase in the amount of mRNA per positive cell. Our findings suggest that TP is playing a role in facilitating transfer or binding of AdDNA to appropriate sites for transgene expression, but does not augment the level of expression for each successfully transcribed genome. In complementing 293 cells (Figure 3 ) at early time points the differences in transgene expression (threefold) in the presence or absence of TP were similar to those observed in A549 cells, again reflecting its ability to enhance the delivery of input AdDNA. However, in 293 cells at later time points the presence of TP resulted in much greater transgene expression, thought to reflect its ability to promote replication. Taken together these data supplement the observations of Sharp et al. 25 who showed the importance of intact TP to AdDNA plaque formation, although the relative importance of TP on increasing transduction of the input virus DNA and on viral replication could not be distinguished from their data.
To explore whether the increased transgene expression seen in Figures 1 and 3 (at early time points) could be conferred on plasmid DNA, pTP was produced and chemically conjugated to the ends of linearised plasmids (Figure 2 ). The frequency of cells expressing the reporter gene was increased approximately fivefold as a result of linkage of pTP to the plasmid, compatible with some enhancement of transfection frequency. However, this was not a specific effect as a similar result was seen using albumin. The effect might therefore reflect, for example, decreased susceptibility of the modified DNA to degradation by exonucleases. Although TP and pTP mediate different roles in the virus life cycle, it is feasible that the there are some overlapping activities. Lieber et al. 26 also studied pTP and reported that the expression from a plasmid with a TP-binding site is enhanced 50-fold when used in cells transiently expressing pTP, concluding this was a result of improved transfer into the nucleus. These observations of a substantial effect of pTP contrast with the relatively minor activity reported in the studies here and demonstrate that the orientation, DNA context or mode of linkage of the pTP have an important influence on its biological activity.
The ability of adenovirus genomes (bearing TP) to enter the replication cycle independent of the presence of other viral proteins makes oncolytic adenovirus a very attractive candidate for delivery at the genetic level using non-viral vectors. While greater potency could theoreti- Synthetic vectors for neutralising antibody resistant RC Carlisle et al cally be achieved using alternative lytic viruses such as vaccinia, their dependence on co-delivery of ancillary viral proteins to enable replication makes their use far less feasible.
The non-viral vectors examined in this study showed an encouraging ability to deliver adenovirus DNA-TP effectively despite the presence of adenovirus-neutralising antibodies. Indeed, whereas the efficiency of initial transduction using DOTAP in vitro was inhibited approximately twofold by neutralising antiserum, perhaps reflecting an activity of anti-TP antibodies, assessments of cytopathic effect using AdDNA-TP delivered with a targeted polyplex showed no inhibition at all by neutralising antiserum present during the delivery phase. While the efficiency of non-viral delivery was much lower than could be achieved using intact virus under ideal conditions, the synthetic vectors were superior to intact virus in the presence of neutralising antiserum. The subsequent ability of viruses to spread from cell to cell in vivo depends on the level of intratumoural neutralising antibodies, although preliminary indications suggest this may not limit success of the approach. 29 Polymer-coated polyplex vectors also provide the possibility for systemic delivery following intravenous injection, with extended plasma kinetics and evidence for tumour accumulation 15, 30 probably mediated through the 'Enhanced Permeability and Retention' effect due to hyperpermeable tumour microvasculature. 31 When retargeted by covalent linkage of appropriate ligands, these vectors have also shown receptor-mediated transduction in vitro and receptor-mediated targeting following intravenous injection in vivo.
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They therefore provide a versatile platform for receptor-mediated delivery of viral DNA to cellular targets both in vitro and in vivo. Based on the observations here it is therefore feasible that such vectors may enable neutralising antibody-resistant delivery of adenovirus genomes to metastatic tumours via the bloodstream, an exciting possibility since many patients already have metastatic disease at the time of initial diagnosis. Delivery via the bloodstream would enable access to disseminated metastases via both arterial (for established tumour growths) and venous (for micrometastases) routes, and would also introduce the virus to those parts of the tumour that are best nourished and oxygenated, potentially maximising virus replication and the opportunity to produce a therapeutic quantity of virus in situ. These possibilities represent an intriguing challenge for the field of virus delivery and are presently the subject of detailed ongoing investigation.
Materials and methods

Adenovirus propagation and storage
AdCMV-GFPDE1 (Ad GFP ) is a replication deficient human type 5 adenovirus lacking E1 (nucleotides 358-3329) and E3 (nucleotides 28593-30470) and encoding green fluorescent protein (GFP) under control of the CMV IE promoter in the E1 region. Similarly Ad luc is an E1, E3-deleted type 5 adenovirus expressing luciferase under the control of the CMV IE promoter. Wild-type adenovirus type 5 (Ad5wt) was also used. Propagation of adenovirus was performed in E1 complementing 293 cells (Ad GFP ) or A549 cells (Ad5wt), virus was isolated using caesium chloride gradient centrifugation. Aliquots were dialysed into PBS with 10% glycerol and stored at À701C.
Purification of adenovirus DNA bearing terminal protein
All treatment and purification of adenovirus genomes with TP (AdDNA-TP) was performed at 41C in order to minimise degradation of the protein. Banded virus was disrupted by mixing with an equal volume of a chilled sterilised solution containing guanidinium chloride (8 M, BDH), Pefabloc (2 mM, Roche, Basel, Switzerland), leupeptin (1 mg/ml), apoptin (1 mg/ml), EDTA (1 mM), Tris (10 mM, pH 8). After incubation on ice for at least 15 min, sample was loaded onto a 40 ml sepharose 4B-200 column, which had been pre-equilibrated with a sterilised solution containing guanidine chloride (4 M), Pefabloc (2 mM), 2-mercaptoethanol (2 mM), leupeptin (1 mg/ml), apoptin (1 mg/ml), EDTA (1 mM), Tris (10 mM, pH 8). The sample was eluted in the same solution (1 ml/min) and the AdDNA-TP separated from Ad proteins by size exclusion. Fractions (1 ml) were collected and assayed for protein content using a BCA assay and DNA content using Hoechst dye. Fractions positive for DNA were grouped and dialysed into three changes of HEPES (10 mM pH 7.5), Pefabloc (2 mM), and EDTA (1 mM) using slydealyzer cassettes (Pierce, Rockford, IL, USA) and stored at 41C. DNA concentration was recalculated using Hoechst dye and the purity verified by calculation of A260/A280. Immunoblots were performed to confirm the presence of terminal protein and PAGE/silver stains conducted to verify the absence of other adenovirus proteins.
Removal of terminal protein from adenovirus DNA
Purified AdDNA-TP was treated with 20 mg/ml proteinase K for 2 h at 371C. The digested terminal protein and proteinase K was then separated away from the AdDNA using a Microspin S-400 HR column (Pharmacia Biotech, Amersham Bucks, UK). The DNA concentration of the resulting filtrate was calculated using Hoechst dye (Sigma, Dorset, UK). A 1.4% agarose gel with 500 ng/ ml ethidium bromide was the used to verify the success of the procedure. Proteinase K treated and non-treated AdDNA-TP was loaded onto the gel and run for 4 h at 30 V, the gel was then analysed using a Typhoon 8600 variable mode imager (Amersham Biosciences, CA, USA). Only samples with intact TP failed to migrate into the gel.
Production of pTP
The recombinant autographa californica polyhedrosis virus (AcNPV) expressing pTP was a kind gift from Professor Ron Hay, University of St Andrews, Scotland. 24 All the AcNPV work was performed with the Spodoptera frugiperda (Sf9) cell line (ECAAC 89070101). Optimal pTP production was achieved by infecting with five AcNPV per cell. When cell viability fell to 10% the infection was ceased. A protocol as described by Webster et al. 24 was followed for the cell harvesting, cell lysis and protein purification using two ion exchange columns. Sample was stored at -701C (after aliquots had been taken for analysis). Sodium dodecyl sulphate (SDS) PAGE and Synthetic vectors for neutralising antibody resistant RC Carlisle et al silver staining/Western blotting were used to identify pTP positive fractions and confirm their purity.
Conjugation of pTP and albumin to linearised plasmid
After dialysis into PBS (0.1 M pH 7.8) pTP or albumin was mixed with a 50-fold molar excess of N-succinimidyl 3-(2-pyridyldisulfanyl)propanoate (SPDP). After 60 min at room temperature the pTP-PDP and albumin-PDP adducts were purified by G-25 Sephadex, concentrations measured using the BCA assay and the content of dithiopyridyl groups was determined from the absorbance change at 343 nm following DTT addition. Plasmid DNA (pGFP-C1, Clontech, USA) was linearised using ApaLI (NEB Biolabs, MA, USA) overnight at 371C. This created a 5 0 overhang containing an unpaired dAMP nucleotide. The linearised DNA (25 mg) was then mixed with; 10 ml 10 Â Klenow buffer, dATP (40 mM), dCTP (40 mM), dGTP (40 mM), 5-(3-aminoallyl)-dUTP (60 mM), acetylated BSA (0.1 mg/ml) and 25 U of Klenow polymerase (all from New England Biolabs). The use of aminoallyl-modified dUTP leads to the incorporation of an available amino group into the DNA. After 3 h at 371C the reaction was stopped by heating to 751C for 10 min and the product purified using a Microspin S-400 HR column. The aminomodified linearised DNA in borate buffer was mixed with a 100-fold molar excess of N-succinimidyl- [4-vinylsulfonyl] benzoate (SVSB), (Pierce Chemical CO, USA). After 3 h at room temperature free SVSB was purified away using a Microspin S-400 HR column. The DNA-vinyl sulphone was then reacted with pTP-PDP or albumin-PDP to give a conjugate. SDS-PAGE and silver staining or Western blotting was used to verify the success of the procedure. Non-conjugated pTP or albumin entered the acrylamide gel freely, either alone or when mixed with linearised plasmid DNA. In contrast pTP-DNA and albumin-DNA conjugates were excluded from the gel, although benzonase treatment degraded the DNA and restored the electrophoretic mobility of the proteins.
Preparation of synthetic vectors for transfection
AdDNA with or without TP was mixed with calf thymus DNA to give a total DNA concentration of 20 mg/ml in 50 mM HEPES pH 7.4. The calf thymus DNA was included to bulk up the total amount of DNA present and aid condensation. The DNA was then condensed with either a fivefold weight excess of DOTAP or with polyethylenimine (PEI) at an N:P ratio of 10 (defined as the ratio of amino groups in the PEI to nucleic acid phosphates). Surface coating of PEI/DNA complexes was achieved by the addition of a hydrophilic polymer PHPMA (poly (N-(2-hydroxypropyl) methacrylamide)) incorporating reducible disulphide bonds and bearing amine reactive thiazolidine groups, to a final polymer concentration of 1 mg/ml. 28 Retargeting of complexes was achieved by the addition of basic fibroblast growth factor (FGF) to a final concentration of 0.14 mg/ml. Complexes were added to cells in the presence of serum and the absence or presence of a 1:100 or 1:10 dilution of rabbit polyclonal anti adenovirus neutralising antibody (R299) raised by immunisation with heat inactivated wild-type Ad5 virus. This antibody has an EC50 of 1 Â 10 5 that is it gives a 50% neutralisation of Adb-Gal (1 Â 10 5 particles per cell) at a dilution of 1 Â 10
5
.
Assay of reporter gene expression
Flow cytometry (FACSCalibur, Becton Dickenson, Oxford, UK) was used to assess the percentage of cells positive for GFP expression and the intensity of that expression. Debris were excluded by size and density gating and diagonal gating of red fluorescence vs green fluorescence allowed identification and quantification of GFP expressing cells. Data were analysed using WinMdi software. Luciferase expression was measured following lysis in Promega lysis solution and luciferase assay reagents and a LB9507 luminometer (Berthold).
Assessment of cytotoxicity
Infections were performed as described in the legend. At the conclusion of cytotoxicity experiments, medium was removed and cells were washed with PBS before assessment of viability using the MTS assay (Promega, WI, USA). Briefly, 20 ml of MTS reagent was added to each well and incubated for 1-2 h at 371C. A Victor plate reader (Wallac 1420) was then used to measure the absorbance at 490 nm and data represented expressed as a percentage of the value obtained with cells exposed to complexes containing calf thymus DNA but no AdDNA-TP.
Intratumoural injections
For studies of antibody resistance 1 Â 10 7 A549 cells were implanted subcutaneously into SCID beige mice and grown for 4 weeks. Ad luc or FGF retargeted polyplex/ Ad luc DNA-TP was mixed on ice with a final dilution of 1:5 neutralising antibody (R299). After 1 h a total 2.3 Â 10 9 genomes were directly injected into each tumour (four injections of 25 ml). After 48 h, tumours were harvested and following homogenisation in lysis solution (Promega, Southampton, UK) luciferase expression was assayed.
For studies of replication 1 Â 10 7 A549 cells were implanted subcutaneously into SCID beige mice and grown for 4 weeks. Each tumour was injected with 2.4 Â 10 10 Ad luc or FGF retargeted polyplex/Ad wt DNA-TP in four injections of 25 ml. After 14 days tumours were harvested and following isolation of DNA (Sigma, genomic DNA isolation kit) QPCR was performed as described previously to ascertain the adenovirus genome copy number present. 12 
